Status and phase
Conditions
Treatments
About
This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).
Full description
Approximately 225 eligible participants will be receive a single dose of either low, medium, or high doses BPL-003, given intranasally, with 8 weeks of follow-up assessments.
Psychological support will be given before, during and after dosing.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
225 participants in 3 patient groups
Loading...
Central trial contact
Beckley Psytech Ltd
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal